Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1997-06-16
1999-11-09
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
424608, A61K 3121
Patent
active
059815795
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention relates to the treatment of disease in animals and is more particularly concerned with a novel pharmaceutical pack and a novel form of treatment for various non-human mammalian diseases and distress conditions.
BACKGROUND TO THE INVENTION
Various form of systemic treatment are prescribed for animals in diseased or distressed conditions. Such treatments involve the administration of medicaments by intravenous, intramuscular or parenteral infusion or injection, by oral administration or by suppositories. However, for a number of animals the prescribed treatments are not easy to administer, particularly if the animal will not eat, or is required to remain still for long periods of time. In other cases the systemic treatments hitherto proposed have been found to be relatively ineffective, especially in relation to diseases of the legs and feet, and systemic and local vascular disorders, or to have undesirable side effects.
SUMMARY OF THE INVENTION
According to the present invention, an animal suffering from a disease or distress condition, or which is liable to suffer therefrom, or susceptible thereto, is treated with an agent active in controlling or preventing such a condition in a composition formulated for topical application.
In a first aspect, the invention provides a pack comprising an active agent for the treatment, prevention, or control of a disease or distress condition comprising: dressing and a composition comprising the active agent formulated for topical application.
In another aspect, the invention provides a method for the treatment, prevention or control of a disease or distress condition comprising: composition comprising an active agent for the treatment, prevention, or control of the disease or distress condition, said composition being provided with a protective covering and/or dressing.
In a further aspect, the invention provides the use of an active agent for the treatment, prevention, or control of a disease or a distress condition comprising: protective covering and/or dressing and a topically applied medicament for the treatment of such disease or distress condition.
DETAILED DESCRIPTION OF THE INVENTION
A pack in accordance with the present invention is preferably adapted to provide a unidirectional outflow of the active agent into the vasculature of the animal and can comprise, for example, a protective covering, which may be a tape or bandage comprising a plastics film or sheet, or a woven or non-woven natural or synthetic fibrous material. The protective covering is preferably flexible and may be resilient or elasticated as appropriate. In preferred embodiments the protective covering comprises an opaque material or other shielding means for protecting the active agent from light rays and/or sunlight.
Preferably the protective covering is provided with means for securing the protective covering to the animal, which means may comprise an adhesive layer coated onto the protective covering, or a layer of Velcro or similar material. Alternatively, the securing means may comprise an adhesive tape or a Velcro cuff or bandage. For use on the legs or feet, the protective covering may comprise a protective boot. For use on the tail, the protective covering may comprise a cuff or sleeve.
The dressing may comprise a gauze, or non-woven pad of fibrous material, and in certain embodiments preferably has absorbent characteristics. The gauze or absorbent pad may be provided with a perforated plastics film layer on the side which is to be in contact with the animal.
In the simplest case, the composition may be provided in a separate container, for example a tube, ampoule, or similar dispenser, applied to the animal topically as appropriate, and then covered with the protective covering and/or dressing. In another, preferred, embodiment, however, the pack comprises an absorbent pad pre-impregnated with the composition comprising the active agent, which is applied to the animal and covered with the protective covering. In this embodiment, the absorbe
REFERENCES:
patent: 4777047 (1988-10-01), Bauer et al.
patent: 5132115 (1992-07-01), Wolter et al.
patent: 5189986 (1993-03-01), Burkoth
Tillman, L.G., et al., "Serum angiotensin converting enzyme activity and response to angiotensin I in horses", Equine Colic, pp. 80-83, 1990.
Bryant, Clare E., et al., "Nitric Oxide: friend or foe?", Equine Veterinary Education, 1994, pp. 59-64.
Young, Stephen, "The Body's Vital Poison,"New Scientist, Mar. 13, 1993, pp. 36-40.
British National Formulary 25, No. 25, Mar. 1993, "2.5.5 Angiotensin-converting enzyme inhibitors", "Captopril", pp. 87-88.
Purohit, Ram C., et al., "Evaluation of Vasoactive Drugs in Equine Hypertension and Laminitis", Proceedings of First Equine Endotoxaemia Meeting, Sep. 1981. pp. 152-159.
Monthly Index of Medical Specialities, Aug. 1992, "Hypertensive", pp. 46-63, 1992.
Dhanakoti, Srinivas N., et al., "Net Renal Arginine Flux in Rats Is Not Affected by Dietary Arginine or Dietary Protein Intake", American Institute of Nutrition, pp. 1127-1134, 1992.
Brusilow, Saul, "Treatment of Urea Cycle Disorders," Treatment of Genetic Diseases, ed. Deswick R.J., 1991, pp. 79-95, published Churchill Livingston, New York.
Galey, F.D., et al., "Antagonism in isolated equine digital vessels of contraction induced by epinephrine in the presence of hydrocortisone and an aqueous extract of black walnut," J. Vet. Pharmacal. Therap. 12:411-420, 1989., pp. 411-419.
Martindale--The Extra Pharmacopoeia, 29th Edition, ed. by James E.F. Reynolds, London, The Pharmaceutical Press, "Antihypertensive Agents," pp. 466-504, 1989.
Martindale--The Extra Pharmacopoeia, 29th Edition, ed. by James E.F. Reynolds, London, The Pharmaceutical Press, "Arginine", p. 1254, 1989.
Martindale--The Extra Pharmacopoeia, 29th Edition, ed. by James E.F. Reynolds, London, The Pharmaceutical Press, "Captopril", p. 468, 1989.
Martindale--13th Edition, London, The Pharmaceutical Press, "Glyceryl Trinitrate" pp. 1020-1023, 1992.
Martindale--13th Edition,, London, The Pharmaceutical Press, "Arginine", pp. 1035-1038, 1992.
Martindale--13th Edition,, London, The Pharmaceutical Press, "Sodium Nitroprusside", pp. 387-389, 1992.
The Merck Index, 11th Edition, ed. by Susan Badavari, Merck & Co., Inc., Rahway, NJ, 1989, "Captopril," pp. 267-268, 1989.
The Merck Index, 11th Edition, ed. by Susan Badavari, Merck & Co., Inc., Rahway, NJ, 1989, "Arginine", p. 808, 1989.
Yelle, Marianne, "Clinicians guide to equine laminitis," Equine Veterinary Journal, 1986, pp. 156-158.
Nickerson, Mark, "Vasodilator Drugs", The Pharmacological Use of Therapeutics, pp. 745-764, 1970.
Abstract: Miller, Warren G., "Acute Equine Laminitis: Renal Morphology and Endocrine Interplay", Texas A&M, 1981.
Abstract: Rossitich, E. Jr., "L-arginine normalizes endothelial function in cerebral vessels from hypercholesterolemic rabbits", J-Clin-Invest, Apr. 1991, 87(4):1295-9.
Abstract: Tillman, L.G., et al., "Serum angiotensin converting enzyme activity and response tot angiotensin in I in horses," Dept. of Pharmaceutics, College of Pharmacy, University of Georgia, Athens, Equine Veterinary Journal (Supp. 7) pp. 80-83, 1989.
Colles, Dr. Chris, "Laminitis Research", Equine Veterinary Journal, vol. 23 (1981), pp. 237-238.
Brosnan, J.T., et al., Department of Biochemistry, Memorial University of Newfoundland, St. Johns., Newfoundland, Canada, A1B 3X9, "Endogenous Arginine Synthesis", 1992.
"Laminitis," Adam Lameness in Horses, 4.sup.th Edition, ed. Stashak TS, Lea & Febiger of Philadelphia, pp. 493-495, 1993.
Henderson Ian William
Hinckley Karen Ann
Jarvis William R. A.
The University of Sheffield
LandOfFree
Use of nitrovasodilators for treatment of disease or stress cond does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of nitrovasodilators for treatment of disease or stress cond, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of nitrovasodilators for treatment of disease or stress cond will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1456689